GPR171

Across TCGA pan-cancer cohorts, GPR171 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GPR171 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher GPR171 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPR171 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, BLCA, and UCEC are the cancer types where GPR171 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.173	0.743	<.001	42	view →
BLCA	OS	Median	All	0.116	0.448	.010	27	view →
UCEC	DFS	Median	II,III,IV	1.000	0.438	.014	22	view →
STAD	OS	Median	III,IV	0.003	0.633	<.001	12	view →
COAD	OS	Median	All	0.111	0.871	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GPR171–CESC (DFS)

Open the CESC breakdown →